Peptide Semaglutide CAS 910463-68-2 5mg 10mg Retatrutide Tirzepatide Liraglutide Melanotan II Peptid

Semax is a kind of nootropic that was extensively developed in Russia in the 1980s-90s. It is used as a treatment for cognitive degeneration and brain damage, especially for victims of stroke.

A synthetic form of the adrenocorticotropic hormone, it is delivered into the body via a Semax nasal spray. It works like regular human hormones in counteracting stress brought about by environmental factors.

A hormone secreted by the pituitary gland, that stimulates the release of cortisol from the adrenal gland, which in turn regulates glucose metabolism and maintains blood pressure.

Retatrutide is an investigational single molecule that activates the body's receptors for three hormones - glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), and is being studied for the treatment of obesity.

It employs a triple-agonist (triple-G) mechanism of action. In addition to being a GLP-1RA, it also targets gastric inhibitory polypeptide receptor (GIPR), and glucagon receptor (GCGR). This has consequently shown increased efficacy benefits in clinical trials, superior to those seen with W, which facilitates around -15% body weight loss.

Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide 1 receptors (GLP1 AR) and used for the treatment of type 2 diabetes. 

It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide.